I agree that Manuso's myriad of presentations does nothing for our share price, but to be accurate, the ASH presentation is from the Leukemia Dept. Chair at the MD Anderson Cancer Institute. Also, investor day in London may signal a shift from old SUPG management to old Astex Pharma management. Hoping Jhoti replaces Manuso in the near future.
From the ASH press release:
Monday, December 10, 2012 at 11:45 am ET. The oral presentation will be made by Hagop M. Kantarjian, MD, professor and department chair, department of leukemia, cancer medicine division, The University of Texas MD Anderson Cancer Center, Houston, TX. The accepted abstract is available on the ASH website
Kantarjian is the real deal. His research on Dacogen helped get the original FDA approval and he published the manuscript that allowed for alternative 5 day dosing schedule. If he is behind the research on SG-I110, that is a great sign. Heard him once say that Dacogen should have been called "Kantarjibine."